In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Consolidation in Cardiac Rhythm Management

Executive Summary

Sulzer Medica's decision to sell Intermedics Inc. was as much a statement about the difficulty of resurrecting its pacemaker business as it was of the company's desire to concentrate on its core orthopedic and cardiovascular prosthetic lines. Guidant Corp. is a natural acquirer. Intermedics helps solidify its position as the number two company in cardiac rhythm management.

You may also be interested in...



Health Care Personnel, Long-Term Care Residents Should Get COVID-19 Vaccine First, ACIP Votes

CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.

Church & Dwight Takes Homeopathic Turn For OTC Sales Driver, Acquires Zicam Marketer Matrixx

C&D CEO Matthew Farrell says Zicam has 73% share in the US zinc-containing wellness product market. It's acquiring marketer Matrixx Initiatives at a price almost 15 times Zicam brand’s projected 2021 EBITDA.

US COVID-19 Fraud: After Facebook Posts, Regulators Don’t ‘Friend’ ChromaDex

ChromaDex is among latest targets of FDA/FTC joint warnings identifying claims on websites as well as in social media posts that render products unapproved and misbranded drugs indicated to prevent or treat COVID-19.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM009163

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel